3v5m: Difference between revisions
No edit summary |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of M69V mutant of SHV beta-lactamase== | |||
<StructureSection load='3v5m' size='340' side='right'caption='[[3v5m]], [[Resolution|resolution]] 1.30Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[3v5m]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Klebsiella_pneumoniae Klebsiella pneumoniae]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3V5M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3V5M FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.3Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MA4:CYCLOHEXYL-HEXYL-BETA-D-MALTOSIDE'>MA4</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3v5m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3v5m OCA], [https://pdbe.org/3v5m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3v5m RCSB], [https://www.ebi.ac.uk/pdbsum/3v5m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3v5m ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The ability of bacteria to express inhibitor-resistant (IR) beta-lactamases is stimulating the development of novel inhibitors of these enzymes. The 2'beta-glutaroxypenicillinate sulfone, SA2-13, was previously designed to enhance the stabilization of the deacylation-refractory, trans-enamine inhibitory intermediate. To test whether this mode of inhibition can overcome different IR mutations, we determined the binding mode of SA2-13 through X-ray crystallography, obtaining co-crystals of the inhibitor-protein complex by soaking crystals of the IR sulfhydryl variable (SHV) beta-lactamase variants S130G and M69V with the inhibitor. The 1.45 A crystal structure of the S130G SHV:SA2-13 complex reveals that SA2-13 is still able to form the stable trans-enamine intermediate similar to the wild-type complex structure, yet with its carboxyl linker shifted deeper into the active site in the space vacated by the S130G mutation. In contrast, data from crystals of the M69V SHV:SA2-13 complex at 1.3 A did not reveal clear inhibitor density indicating that this IR variant disfavors the trans-enamine conformation, likely due to a subtle shift in A237. | |||
The importance of the trans-enamine intermediate as a beta-lactamase inhibition strategy probed in inhibitor-resistant SHV beta-lactamase variants.,Ke W, Rodkey EA, Sampson JM, Skalweit MJ, Sheri A, Pagadala SR, Nottingham MD, Buynak JD, Bonomo RA, van den Akker F ChemMedChem. 2012 Jun;7(6):1002-8. doi: 10.1002/cmdc.201200006. Epub 2012 Mar 21. PMID:22438274<ref>PMID:22438274</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 3v5m" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Beta-lactamase 3D structures|Beta-lactamase 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Klebsiella pneumoniae]] | |||
[[Category: Large Structures]] | |||
[[Category: Rodkey EA]] | |||
[[Category: Van den Akker F]] | |||
Latest revision as of 05:32, 21 November 2024
Crystal structure of M69V mutant of SHV beta-lactamaseCrystal structure of M69V mutant of SHV beta-lactamase
Structural highlights
Publication Abstract from PubMedThe ability of bacteria to express inhibitor-resistant (IR) beta-lactamases is stimulating the development of novel inhibitors of these enzymes. The 2'beta-glutaroxypenicillinate sulfone, SA2-13, was previously designed to enhance the stabilization of the deacylation-refractory, trans-enamine inhibitory intermediate. To test whether this mode of inhibition can overcome different IR mutations, we determined the binding mode of SA2-13 through X-ray crystallography, obtaining co-crystals of the inhibitor-protein complex by soaking crystals of the IR sulfhydryl variable (SHV) beta-lactamase variants S130G and M69V with the inhibitor. The 1.45 A crystal structure of the S130G SHV:SA2-13 complex reveals that SA2-13 is still able to form the stable trans-enamine intermediate similar to the wild-type complex structure, yet with its carboxyl linker shifted deeper into the active site in the space vacated by the S130G mutation. In contrast, data from crystals of the M69V SHV:SA2-13 complex at 1.3 A did not reveal clear inhibitor density indicating that this IR variant disfavors the trans-enamine conformation, likely due to a subtle shift in A237. The importance of the trans-enamine intermediate as a beta-lactamase inhibition strategy probed in inhibitor-resistant SHV beta-lactamase variants.,Ke W, Rodkey EA, Sampson JM, Skalweit MJ, Sheri A, Pagadala SR, Nottingham MD, Buynak JD, Bonomo RA, van den Akker F ChemMedChem. 2012 Jun;7(6):1002-8. doi: 10.1002/cmdc.201200006. Epub 2012 Mar 21. PMID:22438274[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||